BNTC logo

Benitec Biopharma Inc. Stock Price

NasdaqCM:BNTC Community·US$412.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

BNTC Share Price Performance

US$12.46
0.66 (5.59%)
US$12.46
0.66 (5.59%)
Price US$12.46

BNTC Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks
2 Rewards

Benitec Biopharma Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$41.8m

Other Expenses

-US$41.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.24
0%
0%
0%
View Full Analysis

About BNTC

Founded
n/a
Employees
19
CEO
Jerel Banks
WebsiteView website
benitec.com

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Recent BNTC News & Updates

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

Jan 31

Recent updates

No updates